Actively Recruiting
Neoadjuvant Chemotherapy Followed by Chemoradiation Versus Chemoradiation for Stage IIIC Cervical Cancer Patients: A Randomized Phase III Trial
Led by Sun Yat-sen University · Updated on 2022-05-10
280
Participants Needed
1
Research Sites
263 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Evaluate the efficacy and safety of neoadjuvant chemotherapy (NAC) with albumin-bound paclitaxel and carboplatin followed by chemoradiation therapy (CRT) for stage IIIC cervical cancer patients with carcinoma \>4 cm in greatest dimension and/or lymph node \>2cm in short axis.
CONDITIONS
Official Title
Neoadjuvant Chemotherapy Followed by Chemoradiation Versus Chemoradiation for Stage IIIC Cervical Cancer Patients: A Randomized Phase III Trial
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Pathologically confirmed squamous cell, adenocarcinoma, or adenosquamous carcinoma of the uterine cervix
- FIGO 2018 stage IIIC with tumor larger than 4 cm or lymph node larger than 2 cm at diagnosis
- Age between 18 and 70 years
- Eastern Cooperative Oncology Group performance status between 0 and 2
- Adequate organ function
You will not qualify if you...
- Not at initial diagnosis
- Presence of any other kind of tumor
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Sun Yat-sen University Cancer Center
Guangzhou, Guangdone, China, 510000
Actively Recruiting
Research Team
J
Junyun Li, M.D.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here